High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP
Launched by OERTLI INSTRUMENTE AG · Dec 5, 2014
Trial Information
Current as of July 25, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients suffering from primary open-angle glaucoma (POAG) inadequately controlled with maximum tolerated medical therapy and who will be treated with cataract surgery.
- Exclusion Criteria:
- • One eyed patients
- • Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits
- • The presence of extreme narrow angle with complete or partial closure in either eye, except for occludable angles treated with a patent iridectomy
- • Any abnormality preventing reliable applanation tonometry, any opacity or patient uncooperativeness that would restrict adequate examination of the ocular fundus or anterior chamber of either eye
- • The risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's opinion
- • Any clinically significant, serious, or severe medical or psychiatric condition; any condition that, in the investigator's opinion, would interfere with optimal participation in the study or present a special risk to the patient
- • Participation in any other investigational study within 30 days prior to baseline visit
About Oertli Instrumente Ag
Oertli Instrumente AG is a leading Swiss medical technology company specializing in the development and manufacturing of innovative surgical instruments and devices for ophthalmology. With a commitment to enhancing patient care and improving surgical outcomes, Oertli combines cutting-edge technology with a deep understanding of clinical needs. The company emphasizes quality and precision in its products, which are designed to support ophthalmic surgeons in performing complex procedures with efficiency and safety. Through rigorous research and development, Oertli Instrumente AG actively contributes to advancing the field of ophthalmic surgery, ensuring that healthcare professionals have access to reliable and effective tools.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kiel, , Germany
Mumbai, , India
Geneva, , Switzerland
Aswan, , Egypt
Reinach, , Switzerland
Patients applied
Trial Officials
Farhad Hafezi, MD, PhD
Principal Investigator
University of Geneva, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials